Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 319

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer

Open access
Liu, Minetta C., Shields, Peter G., Warren, Robert D., Cohen, Philip, Wilkinson, Mary, Ottaviano, Yvonne L., Rao, Suman B., Eng-Wong, Jennifer, Seillier-Moiseiwitsch, Francoise, Noone, Anne-Michelle, Isaacs, Claudine·2009·Journal of Clinical Oncology

Abstract

Purpose: Five or more circulating tumor cells (CTCs) per 7.5 mL of blood predicts for poorer progression-free survival (PFS) in patients with metastatic breast cancer (MBC). We conducted a prospective study to demonstrate that CTC results correlate strongly with radiographic disease progression at the time of and in advance of imaging. Patients and Methods: Serial CTC levels were obtained in patients starting a new treatment regimen for progressive, radiographically measurable MBC. Peripheral blood was collected for CTC enumeration at baseline and at 3- to 4-week intervals. Clinical outcomes were based on radiographic studies performed in 9- to 12-week intervals. Results: Sixty-eight patients were evaluable for the CTC-imaging correlations, and 74 patients were evaluable for the PFS analysis. Median follow-up was 13.3 months. A statistically significant correlation was demonstrated between CTC levels and radiographic disease progression in patients receiving chemotherapy or endocrine therapy. This correlation applied to CTC results obtained at the time of imaging (odds ratio [OR], 6.3), 3 to 5 weeks before imaging (OR, 3.1), and 7 to 9 weeks before imaging (OR, 4.9). Results from analyses stratified by type of therapy remained statistically significant. Shorter PFS was observed for patients with five or more CTCs at 3 to 5 weeks and at 7 to 9 weeks after the start of treatment. Conclusion: We provide, to our knowledge, the first evidence of a strong correlation between CTC results and radiographic disease progression in patients receiving chemotherapy or endocrine therapy for MBC. These findings support the role of CTC enumeration as an adjunct to standard methods of monitoring disease status in MBC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.20.6664

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 319

Metadata

Authors
Liu, M. C., Shields, P. G., Warren, R. D., Cohen, P., Wilkinson, M., Ottaviano, Y. L., Rao, S. B., Eng-Wong, J., Seillier-Moiseiwitsch, F., Noone, A.-M., & Isaacs, C.
Venue
Journal of Clinical Oncology
Published
2009-11-01
Volume
27
Issue
31
Pages
5153-5159
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2113375770
Cited by
319
References
2
FWCI
6.60
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer. https://app.cochat.ai/papers/10.1200/jco.2008.20.6664
The paper
Liu, M. C., Shields, P. G., Warren, R. D., Cohen, P., Wilkinson, M., Ottaviano, Y. L., Rao, S. B., Eng-Wong, J., Seillier-Moiseiwitsch, F., Noone, A.-M., & Isaacs, C. (2009). Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.20.6664

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.